Dx & Vx Co., Ltd. (KOSDAQ:180400)

South Korea · Delayed Price · Currency is KRW

2,195.00

-55.00 (-2.44%)

At close: Jul 1, 2026

19.03% (1Y)

Market Cap	216.05B +91.3%
Revenue (ttm)	28.48B -8.5%
Net Income	-28.13B
EPS	-455.08
Shares Out	98.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	63,289
Open	2,250.00
Previous Close	2,250.00
Day's Range	2,160.00 - 2,320.00
52-Week Range	1,319.00 - 5,360.00
Beta	-0.04
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Dx & Vx

Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services; medical data; and funeral home operation services. It provides bacterial vaccine for respiratory disease; macular degeneration drug; atopy dermatitis ... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances

Founded 2001

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 180400

Full Company Profile

Financial Performance

In 2025, Dx & Vx's revenue was 29.36 billion, a decrease of -13.52% compared to the previous year's 33.95 billion. Losses were -29.04 billion, -38.26% less than in 2024.

Financial Statements